Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation.
We have studied the feasibility of using DNA restriction fragment-length polymorphisms (RFLP) to study marrow engraftment in 27 patients after allogeneic bone marrow transplantation, and have compared these results with those obtained using red blood cell antigens, cytogenetics, and immunoglobulin allotypes. Using highly polymorphic DNA probes, we have documented stable chronic mixed hematopoietic chimerism, have identified transient mixed chimeras, have excluded mixed chimerism with high probability in retrospective studies even when a pretransplant DNA sample was not available, have documented marrow engraftment in the early posttransplant period, and have studied the origin of leukemic cells in patients with recurrent disease. We have evaluated the advantages and disadvantages of several genetic markers and have developed tentative statements concerning the prognosis of patients with mixed chimerism. We conclude that DNA RFLP are powerful and practical genetic markers in bone marrow transplantation studies and that further studies of mixed hematopoietic chimerism are warranted.
D000954:Antigens, Surface / Q000032:analysis; D016026:Bone Marrow Transplantation; D002678:Chimera; D004273:DNA, Neoplasm / Q000032:analysis; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D005819:Genetic Markers; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000032:analysis; D006801:Humans; D007126:Immunoglobulin Allotypes / Q000032:analysis; D007938:Leukemia / Q000235:genetics / Q000628:therapy; D008297:Male; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D012008:Recurrence; D012189:Retrospective Studies
D000954:Antigens, Surface; D004273:DNA, Neoplasm; D005819:Genetic Markers; D007126:Immunoglobulin Allotypes